Oncology Exchange:
New and Emerging Therapies for Metastatic Melanoma

A series of Live Grand Rounds Programs, an ASCO®* State Affiliate Meeting, and an On-demand Webcourse.

Welcome to New and Emerging Therapies for Metastatic Melanoma. This CME-certified initiative is intended for community-based oncologists, dermatologists, dermatologic surgeons, and other healthcare professionals involved in the care of patients with melanoma. A series of live CME-certified programs will be presented at selected hospitals and an ASCO®* State Affiliate meeting throughout the US during 2015/2016, and an online CME-certified webcourse will be available in fall of 2015.

*ASCO is a registered trademark of the American Society of Clinical Oncology. These programs are not ASCO events.

Program Description

Recent advances in the treatment of melanoma using immunotherapies and other targeted agents have led to a widening of the gap between evidence-based treatment recommendations and the practice patterns of community oncologists, dermatologists, and other health care professionals who treat patients with metastatic melanoma in the community setting. There is an increasing awareness of the need for effective collaboration between oncologists, dermatologists, and surgeons on the multidisciplinary cancer care team that treats patients with melanoma.

New and Emerging Therapies for Metastatic Melanoma will educate community clinicians on the mechanisms of action of novel agents, the efficacy and safety of recently approved single-agents and combination therapies, the benefits of a multidisciplinary treatment approach, and the need to empower melanoma patients to actively participate in treatment planning.

Learning Objectives

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Evaluate the efficacy and safety of approved and emerging therapies for metastatic melanoma
  • Explain the value of a multidisciplinary approach for the treatment of melanoma to improve patient outcomes
  • Recognize the importance of patients actively participating in their treatment decisions and health management

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology.The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please email contact@potomacme.org.

Calendars for Live Activities

If you are interested in attending a meeting in your local area, please contact Kathy Whyte at 443-909-7901 or kwhyte@rockpointe.com for the schedule.

Calendars for Live Activities

Back to Top

Visiting Professor Series

Chapter Meetings

Related Online Offerings

Back to Top

Click here [Coming Soon] for the CME-certified webcourse associated with this program.

Click here for the CME-certified webcourse associated with this program.

LIVE PROGRAM MATERIALS FOR SPEAKERS AND ADMINISTRATORS

Back to Top

I. Administrator Material

II. Speaker Material

Audio Orientation

Thank you for joining us as an expert speaker for the 2015 Grand Rounds Series, New and Emerging Therapies for Metastatic Melanoma.

This orientation will familiarize you with the complete slide set, provide insight from the program steering committee, and address potential questions. During the audio lecture, the following key topics will be discussed:

  • Efficacy and safety of approved and emerging therapies for metastatic melanoma
  • The value of a multidisciplinary approach for the treatment of melanoma to improve patient outcomes
  • The importance of patients actively participating in treatment decisions and health management

Transcript of Speaker Orientation Download (PDF) [Coming Soon]

Audio download of Speaker Orientation Audio [Coming Soon]

Transcript of Speaker Orientation Download (PDF)

Audio download of Speaker Orientation
Audio Download

CME-certified ProgramSlides

This version of the program slides has been CME-certified and these slides are to be used for this activity. Download (PowerPoint) [Coming Soon]

This version of the program slides has been CME-certified and these slides are to be used for this activity. Download (PowerPoint)

Steering Committee and Speaker Biographies

Paul B. Chapman, MD Paul B. Chapman, MD

Section Head, Melanoma
Attending Physician
Melanoma & Immunotherapeutics Service
Professor of Medicine, Weill Cornell Meidcal Center
New York, NY

Paul B. Chapman, MD is an Attending Physician at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College. He graduated from Cornell University Medical College and completed internship and residency training in internal medicine at the University of Chicago. His medical oncology fellowship was completed at Memorial Sloan-Kettering. He is board-certified in internal medicine and medical oncology and has spent his career working on melanoma, a deadly and common form of skin cancer.

Dr. Chapman was in the laboratory of Alan Houghton and focused initially on immunotherapy of melanoma. He conducted clinical and laboratory research on the question of immune recognition of melanoma, which included developing a vaccine against GD3 ganglioside and conducting pre-clinical and clinical studies that culminated in an international, randomized phase III trial. Recently, his clinical research has focused on inhibitors of kinases that are mutated or otherwise critical for melanoma growth. He was the Principal Investigator for the phase III randomized trial that led to FDA approval of vemurafenib and dabrafenib, the first BRAF inhibitors for melanoma. Dr. Chapman has authored/co-authored more than 150 publications in melanoma.

Vernon K. Sondak, MD Vernon K. Sondak, MD

Department Chair, Cutaneous Oncology
Director, Surgical Education
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL

Vernon K. Sondak, MD MD is Chair of the Department of Cutaneous Oncology and Director of Surgical Education at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, FL. He is also a Professor in the Departments of Oncologic Sciences and Surgery at the University of South Florida Morsani College of Medicine. His research interests include surgical treatment of malignant melanoma in adults and children; surgical treatment of Merkel cell carcinoma, desmoid tumors, and cutaneous soft-tissue sarcomas, including dermatofibrosarcoma protuberans; adjuvant and neoadjuvant therapy of melanoma; and evaluation of new therapies for patients with localized or disseminated melanoma.

Dr. Sondak has also been a leader in studies of surgical treatment of melanoma and other cutaneous malignancies, particularly in the application of sentinel lymph-node biopsy to the staging of melanoma and Merkel cell carcinoma. He is actively involved in ongoing analyses to determine which patients with thin melanoma are most likely to benefit from sentinel node biopsy, as well as which patients with sentinel node metastases are most likely to have further metastases identified in other regional lymph nodes. Dr. Sondak is the author or co-author of more than 335 articles in peer-reviewed publications, 176 abstracts, 8 books, and 67 book chapters.

Back to Top

Jointly provided by Potomac Center for Medical Education and Rockpointe Oncology

This activity is supported by educational grants from Genentech and Novartis Pharmaceuticals Corporation.

©2015 Rockpointe